• GW Urological Oncology Program
  • Multi-Disciplinary, Patient Centered Cancer Care
  • The GW Cancer Center offers advanced treatment in urology, including minimally invasive, laparoscopic surgery for the management of urinary, prostate, kidney, and pelvic disorders.

Program Information

Free Prostate Cancer Screenings

Men between the ages of 40 and 70, without a history of prostate cancer, can receive a FREE prostate cancer screening, including a digital rectal exam and Prostate-Specific Antigen (PSA) blood test.

Date and Time: Offered the THIRD Friday of every month from 8:30 a.m to 11:30 a.m. by appointment.

Location: MFA Ambulatory Care Center, 22nd and I Streets, NW, Washington, DC 20037. One block from the Foggy Bottom Metro (Blue and Orange Lines)

Limited Availability. Register Today.

To schedule an appointment for a FREE prostate cancer screening, call 202-741-3106. Click here for more information and a printer-friendly information sheet. 

The da Vinci® Surgical System

Robotic Prostatectomy a minimally invasive method of removing the prostate gland through advancements in robotics and computer technology. Using the the da Vinci robot, surgeons have more precision which lowers the risk of incontinence and impotence for patients when compared to standard prostate cancer surgery. More prostate cancer surgeries, using the da Vinci robot, are performed at The George Washington University Hospital, a partner of the GW Cancer Center, than at any other hospital in the region.

Specialized Cancer Screening, Genomic Testing, & Imaging offered at the GWU MFA:
Prostate Cancer
Prior to Prostate Biopsy
  1. 4KScore blood test - http://4kscore.com/
  2. Prostate Health Index (PHI) blood test - http://prostatehealthindex.us/
  3. SelectMDx tissue test - http://mdxhealth.com/selectmdx-prostate-cancer

During Prostate Biopsy

  1. UroNav MRI-Ultrasound Fusion biopsy - http://www.invivocorp.com/solutions/prostate-solutions/uronav/

After Prostate Biopsy

  1. ConfirmMDx - http://mdxhealth.com/confirmmdx-prostate-cancer
  2. Oncotype DX - http://www.genomichealth.com/en-US/oncotype_iq_products/oncotype_dx/oncotype_dx_prostate_cancer
  3. Decipher - http://deciphertest.com/
Bladder Cancer
  1. Cysview® Blue Light cystoscopy - https://www.cysview.com/blue-light-cystoscopy-with-cysview-2/what-is-blue-light-cystoscopy-with-cysview/
Other Helpful Resources

Institution Websites

  1. GW Cancer Center - http://cancercenter.gwu.edu/
  2. American Urological Association: www.auanet.org

Cancer Information Resources for Patients & their Families

  1. Urology Care Foundation: www.urologyhealth.org
  2. Prostate Cancer Foundation: www.pcf.org
  3. Bladder Cancer Advocacy Network (BCAN): www.bcan.org
  4. American Cancer Society: http://www.cancer.org/cancer/index

Clinical Trials Information

  1. GUMDROP (GenitoUrinary Multidisciplinary DC Regional Oncology Project): www.gumdroptrials.org/
  2. Clinical Trials at the US National Institutes of Health (NIH): https://clinicaltrials.gov
Title Description
A Phase III, Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

Men with newly diagnosed metastatic hormone sensitive prostate cancer and a PSA =2 ng/mL with be randomized to either Androgen deprivation therapy (LHRHa) + TAK-700 (ARM 1) or Androgen deprivation therapy (LHRHa) + Bicalutamide (ARM 2, also the standard of care arm). Patients will be followed for 10 years.

ARN-509-003: A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with non-Metastatic (M0) Castration-Resistant Prostate Cancer

This is a randomized (2:1) trial evaluating the safety and efficacy of ARN-509 versus placebo in men with high risk (M0), non-metastatic castraction resistant prostate cancer (NM-CRPC), defined as PSA doubling time (PSADT) = 10 months

S0931:A Phase III Trial of Everolimus for Renal Cell Ensuing Surgical Therapy

This study is for renal cancer patients who have undergone full surgical resection (radical nephrectomy or partial nephrectomy). Patients must be considered pathologically either intermediate hight risk or very high risk for recurrence.

GWCC Urological Oncology Program
2150 Pennsylvania Ave, NW 2nd Floor
Washington , DC
United States

Schedule an Appointment